Mounjaro and Anxiety: Can Tirzepatide Affect Your Mental Health?

Mounjaro and anxiety are two topics that patients frequently raise with their prescribing clinician, yet there is surprisingly little clear guidance available. If you are taking tirzepatide for weight loss and wondering whether it could affect your mood, your worry is understandable. Rapid physical changes, new medication routines, and the emotional weight of managing obesity can all feed into existing anxious feelings.

This guide examines what the clinical evidence actually shows about tirzepatide and anxiety, whether Mounjaro can be taken safely alongside anxiety medication, and what steps you can take if your mental health shifts during treatment at CutKilo’s Harley Street clinic. If you are specifically concerned about depression, our separate guide on whether Mounjaro can cause depression covers that topic in detail.

Current evidence does not support a causal link between Mounjaro and increased anxiety. In fact, large observational studies suggest the opposite. A 2024 analysis of over three million patient records found that people taking tirzepatide were up to 60 per cent less likely to receive an anxiety diagnosis compared with matched controls not using GLP-1 medication. Both the MHRA and the EMA have reviewed safety reports on GLP-1 receptor agonists and concluded that the available data do not support a link with psychiatric adverse events, including anxiety and suicidal ideation.

That said, some patients do report heightened anxiety during treatment, often related to gastrointestinal side effects, body image changes, or the emotional adjustment that accompanies significant weight loss.

The strongest data come from a large-scale retrospective study published in 2024, which analysed insurance claims from more than three million patients with type 2 diabetes. Patients prescribed tirzepatide showed a significantly lower rate of new anxiety diagnoses compared with those on other treatments, with reductions of approximately 60 per cent. Tirzepatide showed the greatest reduction in anxiety risk among all GLP-1 receptor agonists studied.

A separate real-world cohort study published in Frontiers in Psychiatry in 2025 found that tirzepatide was associated with a 48 per cent lower risk of suicidal ideation or attempts, further supporting the position that this medication does not worsen psychiatric outcomes in the general population.

In the SURMOUNT clinical trial programme, which enrolled over 5,000 participants across multiple phases, psychiatric adverse events were rare and occurred at similar rates in both the tirzepatide and placebo groups. No signal for increased anxiety was identified.

It is important to note that these findings are observational and do not prove that tirzepatide directly reduces anxiety. People who lose weight and feel physically better may naturally experience improved mental health, making it difficult to separate the drug’s direct effects from the benefits of weight loss itself.

Researchers have proposed several mechanisms through which GLP-1 receptor agonists like tirzepatide might affect mood and anxiety, though none has been definitively confirmed in human clinical trials.

GLP-1 receptors are expressed in several brain regions involved in emotional regulation, including the amygdala and hippocampus. Animal studies have demonstrated that activating these receptors can reduce anxiety-like behaviour in rodent models, though translating these findings to human experience requires caution.

Chronic low-grade inflammation is increasingly recognised as a contributing factor in anxiety disorders. Tirzepatide has been shown to reduce markers of systemic inflammation, including C-reactive protein, which could theoretically support improved mental health over time.

Perhaps the most intuitive pathway is indirect: successful weight management often leads to improved sleep quality, greater physical mobility, enhanced self-confidence, and reduced social stigma. Each of these factors is independently associated with lower anxiety levels, and together they may account for much of the improvement patients report.

While population-level data are reassuring, individual experiences vary. Some CutKilo patients report temporary increases in anxiety during the early weeks of treatment, and there are recognisable patterns behind this.

Gastrointestinal side effects such as nausea, vomiting, or changes in appetite can provoke health-related worry, particularly in patients who already tend towards anxious thinking. The physical discomfort itself can heighten the body’s stress response.

Rapid changes in body weight and shape can trigger complex emotional responses. Some patients experience a disconnect between their new physical appearance and their established sense of identity. This is a well-documented psychological phenomenon that is not specific to Mounjaro but can accompany any significant weight loss.

The structured dose escalation schedule, which involves increasing the injection strength every four weeks, can also cause anticipatory anxiety. Patients may worry about side effects worsening at higher doses, even when their body has tolerated previous steps well.

If you notice a persistent shift in your mood or anxiety levels after starting Mounjaro, it is important to raise this with your prescribing clinician. At CutKilo, we monitor our patients’ wellbeing throughout treatment and can adjust the dose or pacing to support both your physical and mental health goals.

There are no known pharmacological interactions between tirzepatide and the most commonly prescribed anxiety medications, including selective serotonin reuptake inhibitors (SSRIs) such as sertraline and citalopram, serotonin-noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine, and benzodiazepines such as diazepam.

Tirzepatide is a peptide-based medication administered by subcutaneous injection, so it bypasses the liver’s first-pass metabolism that governs many drug interactions. It does not inhibit or induce the cytochrome P450 enzyme system responsible for metabolising most psychiatric medications.

However, because tirzepatide slows gastric emptying, oral medications may be absorbed at a different rate during the first few weeks of treatment. For most psychiatric drugs, this has no clinically meaningful effect, but patients taking medications with narrow therapeutic windows should inform both their GP and their weight loss clinician.

Your CutKilo prescriber will review your full medication history before starting treatment and can liaise with your mental health team if needed.

In 2023, both the UK’s Medicines and Healthcare products Regulatory Agency and the European Medicines Agency launched formal reviews into reports of psychiatric side effects associated with GLP-1 receptor agonists, including reports of suicidal ideation, self-harm, and depression.

The MHRA published its findings in September 2024, concluding that the available data do not support a causal association between GLP-1 receptor agonists and psychiatric reactions. No changes to product labelling were recommended.

The EMA’s Pharmacovigilance Risk Assessment Committee reached the same conclusion in April 2024, stating that the evidence does not establish a causal link between these medications and suicidal or self-injurious thoughts and actions.

A systematic review and meta-analysis published in 2025 pooled data from large randomised controlled trials, including cardiovascular outcome studies involving tens of thousands of participants. The analysis found no increased risk of suicidal ideation or behaviour compared with placebo across all GLP-1 receptor agonists studied.

These regulatory and academic reviews provide strong reassurance that GLP-1 medications, including tirzepatide, do not carry an elevated psychiatric risk at the population level.

If you experience anxiety during your treatment, several practical strategies can help.

Keep a brief daily mood log alongside your weight and symptom tracking. This helps your clinician distinguish between medication-related changes and pre-existing patterns.

Maintain regular physical activity. Exercise is one of the most effective evidence-based interventions for anxiety, and it also supports lean mass preservation during weight loss. Our guide to exercise on Mounjaro covers how to structure a safe programme while taking tirzepatide.

Prioritise sleep. Poor sleep and anxiety form a bidirectional cycle, and Mounjaro’s appetite-suppressing effects mean some patients eat too little in the evening, disrupting their sleep. Aim for a small, protein-rich evening meal.

Stay connected with your prescribing team. At CutKilo, we schedule regular check-ins throughout your treatment journey and can adjust your dose timeline if anxiety becomes problematic.

If your anxiety is severe or worsening, speak to your GP about a referral for cognitive behavioural therapy (CBT) or review of your current medication. Treating anxiety and managing weight are not competing goals, and both can be supported simultaneously.

Does Mounjaro cause anxiety? There is no evidence that Mounjaro causes anxiety. Large observational studies and regulatory reviews from the MHRA and EMA have found no causal link between tirzepatide and psychiatric adverse events. Some patients experience temporary anxiety related to side effects or the emotional impact of rapid weight loss, which typically resolves with clinical support.

Can I take Mounjaro with my anxiety medication? Yes. There are no known drug interactions between tirzepatide and commonly prescribed anxiety medications, including SSRIs, SNRIs, and benzodiazepines. Your CutKilo prescriber will review your full medication list before starting treatment.

Will my anxiety get worse when I increase my Mounjaro dose? Dose escalation does not typically increase anxiety as a direct pharmacological effect. Some patients feel anticipatory worry about potential side effects at higher doses, but this usually settles once they see that their body tolerates the increase well. Your clinician can slow the dose schedule if needed.

Has anyone reported mood changes on Mounjaro? In a 2024 safety analysis, approximately 1.2 per cent of reported adverse events were psychiatric in nature, with depression more commonly reported than anxiety. However, the overall rate is low and consistent with background rates in the general population being treated for obesity.

Should I stop Mounjaro if I feel anxious? Do not stop your medication without consulting your prescriber. If you notice a persistent change in your mood or anxiety levels, contact your CutKilo clinician. We can adjust your treatment plan while keeping your weight loss goals on track.

The current evidence is reassuring: tirzepatide does not appear to cause or worsen anxiety, and large-scale observational data suggest it may be associated with a lower risk of anxiety diagnoses. Both the MHRA and EMA have reviewed the available safety data and found no causal link between GLP-1 receptor agonists and psychiatric adverse events. If you do experience anxiety during treatment, practical strategies and clinical support can help, and there is no reason to stop treatment without medical guidance.